| KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Petra BLAHOVCOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vit PROCHAZKA, Andrea JANIKOVA, Martina VASKOVA, Ester MEJSTRIKOVA, Roman KODET, Jan TRKA a Marek TRNENY. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. Hematological Oncology. MALDEN, USA: WILEY-BLACKWELL, 2018, roč. 36, č. 5, s. 773-778. ISSN 0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2550. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1489197,
author = {Klener, Pavel and Fronkova, Eva and Kalinova, Marketa and Belada, David and Forsterova, Kristina and Pytlik, Robert and Blahovcova, Petra and Simkovic, Martin and Šálek, David and Mocikova, Heidi and Prochazka, Vit and Janikova, Andrea and Vaskova, Martina and Mejstrikova, Ester and Kodet, Roman and Trka, Jan and Trneny, Marek},
article_location = {MALDEN, USA},
article_number = {5},
doi = {http://dx.doi.org/10.1002/hon.2550},
keywords = {elderly patients; maintenance rituximab; mantle cell lymphoma; minimal residual disease; PET-CT},
language = {eng},
issn = {0278-0232},
journal = {Hematological Oncology},
title = {Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance},
volume = {36},
year = {2018}
}
TY - JOUR
ID - 1489197
AU - Klener, Pavel - Fronkova, Eva - Kalinova, Marketa - Belada, David - Forsterova, Kristina - Pytlik, Robert - Blahovcova, Petra - Simkovic, Martin - Šálek, David - Mocikova, Heidi - Prochazka, Vit - Janikova, Andrea - Vaskova, Martina - Mejstrikova, Ester - Kodet, Roman - Trka, Jan - Trneny, Marek
PY - 2018
TI - Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance
JF - Hematological Oncology
VL - 36
IS - 5
SP - 773-778
EP - 773-778
PB - WILEY-BLACKWELL
SN - 02780232
KW - elderly patients
KW - maintenance rituximab
KW - mantle cell lymphoma
KW - minimal residual disease
KW - PET-CT
N2 - Rituximab maintenance (RM) prolongs survival of elderly patients with mantle cell lymphoma (MCL). Persistent minimal residual disease (MRD) after induction repeatedly correlated with shorter progression-free survival (PFS). However, none of the published studies analyzed patients treated with RM. The main purpose was to analyze prognostic significance of MRD in the elderly patients with newly diagnosed MCL treated according to the recently published observational trial protocol (alternation of R-CHOP and R-cytarabine, 3 + 3 cycles, GovTrial number NCT03054883) at the centers that implemented RM. Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy. Prognostic significance of MRD was analyzed in a subcohort of patients treated at the centers that implemented RM as a standard approach. Bone marrow proved to be a significantly more sensitive source for MRD detection than peripheral blood. In either compartment MRD (positive versus negative) after 3 or 6 cycles of the induction therapy did not correlate with PFS. The observed loss of prognostic significance of MRD after the R-CHOP-based induction appears to be a consequence of RM immune control over the residual lymphoma.
ER -
KLENER, Pavel, Eva FRONKOVA, Marketa KALINOVA, David BELADA, Kristina FORSTEROVA, Robert PYTLIK, Petra BLAHOVCOVA, Martin SIMKOVIC, David ŠÁLEK, Heidi MOCIKOVA, Vit PROCHAZKA, Andrea JANIKOVA, Martina VASKOVA, Ester MEJSTRIKOVA, Roman KODET, Jan TRKA a Marek TRNENY. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. \textit{Hematological Oncology}. MALDEN, USA: WILEY-BLACKWELL, 2018, roč.~36, č.~5, s.~773-778. ISSN~0278-0232. Dostupné z: https://dx.doi.org/10.1002/hon.2550.
|
